For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged.
Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs and causes damage to the heart.
Bayer was paid $14 million upfront by Roivant for global rights to mosliciguat and will be eligible for another $280 million in milestone-based payments, plus royalties on sales, Roivant said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
